Treatment of NASH with gemcabene
AssigneeGemphire Therapeutics Inc.
InventorsCharles L. Bisgaier, Daniela Carmen Oniciu
Life of this patent
Estimating the term…
Abstract
Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
Claims15
A method of stabilization or reduction of the NAFLD activity score (NAS) in a subject, wherein the subject has a NAS of ≧2, comprising administering to the subject the compound
- or a pharmaceutically acceptable salt thereof
- wherein the subject's NAS is different by no less than 1.5 points after 6 months of treatment with gemcabene.
A method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject gemcabene, wherein the daily dose of the compound
- or a pharmaceutically acceptable salt thereof, administered is from about 50 mg to about 900 mg, wherein the administration of gemcabene or the pharmaceutically acceptable salt thereof slows the progression of hepatic fibrosis or reduces hepatic fibrosis in the subject.
Dependencies are inferred from the claim text.